Immune cell recruitment and cell-based system for cancer therapy

Pharmaceutical Research

Volumn 25, Issue 4, 2008, Pages 752-768

  Gao, Jian Qing ^a,b   Okada, Naoki ^b   Mayumi, Tadanori ^c   Nakagawa, Shinsaku ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b OSAKA UNIVERSITY   (Japan)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Cancer immunotherapy; Cell recruitment; Cell based system; Chemokine; Chemokine receptor; Dendritic cell

Indexed keywords

ADENOVIRUS VECTOR; ALPHA CHEMOKINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CANCER VACCINE; CHEMOKINE; CISPLATIN; CPG 7909; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CX3C CHEMOKINE; CYTOKINE; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 2; LIPOFECTAMINE; LIPOPLEX; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1ALPHA; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKER RECEPTOR 9 AGONIST; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL THERAPY; COXSACKIE VIRUS; DENDRITIC CELL; GENE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MELANOMA; MONOCYTE CHEMOTACTIC PROTEIN 1 GENE; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ADOPTIVE TRANSFER; ANIMALS; CHEMOKINES; CHEMOTAXIS; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE; TREATMENT OUTCOME;

EID: 43349103093     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9443-9     Document Type: Review

References (174)

1. M. Schuster, A. Nechansky, and R. Kircheis. Cancer immunotherapy. Biotechnol. J. 1:138-147 (2006).
2. T. Hinz, C. J. Buchholz, S. T. van der, K. Cichutek, and U. Kalinke. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J. Immunother. 29:472-476 (2006).
3. G. P. Dunn, C. M. Koebel, and R. D. Schreiber. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848 (2006).
4. J. N. Blattman and P. D. Greenberg. Cancer immunotherapy: a treatment for the masses. Science 305:200-205 (2004).
5. M. Whelan, J. Whelan, N. Russell, and A. Dalgleish. Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today 8:253-258 (2003).
6. S. A. Rosenberg. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350:1461-1463 (2004).
7. K. M. Hege, K. Jooss, and D. Pardoll. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol. 25:321-352 (2006).
8. M. Kurooka and Y. Kaneda. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 67:227-236 (2007).
9. C. Palena, S. I. Abrams, J. Schlom, and J. W. Hodge. Cancer vaccines: preclinical studies and novel strategies. Adv. Cancer Res. 95:115-145 (2006).
10. S. Liu, B. A. Foster, T. Chen, G. Zheng, and A. Chen. Modifying dendritic cells via protein transfer for antitumor therapeutics. Clin. Cancer Res. 13:283-291 (2007).
11. L. Zhang, J. R.Conejo-Garcia, D. Katsaros, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213(2003).
12. E. Sato, S. H. Olson, J. Ahn, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102:18538-18543(2005).
13. A. K. Eerola, Y. Soini, and P. Paakko. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6:1875-1881 (2000).
14. X. Y. Yin, M. D. Lu, Y. R. Lai, L. J. Liang, and J. F. Huang. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 50:1281-1284 (2003).
15. A. Fukunaga, M. Miyamoto, Y. Cho, S. Murakami, Y. Kawarada, T. Oshikiri, K Kato., T. Kurokawa, M. Suzuoki, Y. Nakakubo, K. Hiraoka, T. Itoh, T. Morikawa, S. Okushiba, S. Kondo, and H. Katoh. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:e26-e31 (2004).
16. Y. Naito, K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, H. Nagura, and H. Ohtani. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491-3494 (1998).
17. S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159-1166 (1994).
18. O. Mandelboim, E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1:1179-1183 (1995).
19. R. M. Conry, D. T. Curiel, T. V. Strong, S. E. Moore, K. O. Allen, D. L. Barlow, D. R. Shaw, and A. F. LoBuglio. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8:2782-2787 (2002).
20. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90:3539-3543 (1993).
21. H. Asada, T. Kishida, H. Hirai, E. Satoh, S. Ohashi, M. Takeuchi, T. Kubo, M. Kita, Y. Iwakura, J. Imanishi, and O. Mazda. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol. Ther. 5:609-616 (2002).
22. J. I. Mayordomo, T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302 (1995).
23. W. Song, H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. Moore, and R. G. Crystal. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-1256 (1997).
24. S. K. Nair, A. Heiser, D. Boczkowski, A. Majumdar, M. Naoe, J. S. Lebkowski, J. Vieweg, and E. Gilboa. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6:1011-1017 (2000).
25. K. Petrak. Essential properties of drug-targeting delivery systems. Drug Discov. Today 10:1667-1673 (2005).
26. T. Minko, S. S. Dharap, R. I. Pakunlu, and Y. Wang. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 5:389-406 (2004).
27. S. A. Wissing, O. Kayser, and R. H. Muller. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56:1257-1272 (2004).
28. C. C. Muller-Goymann. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur. J. Pharm. Biopharm. 58:343-356 (2004).
29. O. Yoshie, T. Imai, and H. Nomiyama. Chemokines in immunity. Adv. Immunol. 78:57-110 (2001).
30. A. Zlotnik, and O. Yoshie. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127 (2000).
31. V. I. Slettenaar, and J. L. Wilson. The chemokine network: a target in cancer biology?. Adv. Drug Deliv. Rev. 58:962-974 (2006).
32. A. Imaizumi, M. Torisu, and T. Yoshida. A chemotactic factor for rat thymocytes may regulate T-lymphocyte migration toward the thymic microenvironment. Cell. Immunol. 108:53-63 (1987).
33. D. Wang, H. Wang, J. Brown, T. Daikoku, W. Ning, Q. Shi, A. Richmond, R. Strieter, S. K. Dey, and R. N. DuBois. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med. 203:941-951 (2006).
34. T. Tsuchiyama, Y. Nakamoto, Y. Sakai, Y. Marukawa, M. Kitahara, N. Mukaida, and S. Kaneko. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J. Immunol. 178:574-583 (2007).
35. U. Thanarajasingam, L. Sanz, R. Diaz, J. Qiao, L. Sanchez-Perez, T. Kottke, J. Thompson, J. Chester, and R. G. Vile. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 67:300-308 (2007).
36. F. Nishimura, J. E. Dusak, J. Eguchi, X. Zhu, A. Gambotto, W. J. Storkus, and H. Okada. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 66:4478-4487 (2006).
37. T. Ishida, T. Ishii, A. Inagaki, H. Yano, S. Kusumoto, M. Ri, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 20:2162-2168 (2006).
38. K. Flanagan, R. T. Glover, H. Horig, W. Yang, and H. L. Kaufman. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine 22:2894-2903 (2004).
39. J. Q. Gao, Y. Tsuda, K. Katayama, T. Nakayama, Y. Hatanaka, Y. Tani, H. Mizuguchi, T. Hayakawa, O. Yoshie, Y. Tsutsumi, T. Mayumi, and S. Nakagawa. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res. 63:4420-4425 (2003).
40. N. Okada, J. Q. Gao, A. Sasaki, M. Niwa, Y. Okada, T. Nakayama, O. Yoshie, H. Mizuguchi, T. Hayakawa, T. Fujita, A. Yamamoto, Y. Tsutsumi, T. Mayumi, and S. Nakagawa. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host s immune system: implications for chemokine-based cancer immunotherapy. Biochem. Biophys. Res. Commun. 317:68-76 (2004).
41. C. G. Figdor, I. J. de Vries, I, W. J. Lesterhuis, and C. J. Melief. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480 (2004).
42. J. Banchereau and R. M. Steinman. Dendritic cells and the control of immunity. Nature 392:245-252 (1998).
43. Z. Chen, D. Xia, X. Bi, A. Saxena, N. Sidhu, A. El-Gayed, and J. Xiang. Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. J. Gene Med. 7:506-517 (2005).
44. G. Hintzen, L. Ohl, M. L. del Rio, J. I. Rodriguez-Barbosa, O. Pabst, J. R. Kocks, J. Krege, S. Hardtke, and R. Forster. Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node. J. Immunol. 177:7346-7354 (2006).
45. T. Osada, T. M. Clay, C. Y. Woo, M. A. Morse, and H. K. Lyerly. Dendritic cell-based immunotherapy. Int. Rev. Immunol. 25:377-413 (2006).
46. J. Yang and A. Richmond. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9:846-855 (2004).
47. C. Guiducci, C. E. Di, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol. 172:4026-4036 (2004).
48. M. Burnet. Cancer; a biological approach. I. The processes of control. Br. Med. J. 1:779-786 (1957).
49. O. Stutman. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534-536 (1974).
50. V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111 (2001).
51. J. N. Blattman and P. D. Greenberg. Cancer immunotherapy: a treatment for the masses. Science 305:200-205 (2004).
52. B. Wiemann and C. O. Starnes. Coley s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64:529-564 (1994).
53. J. Copier and A. Dalgleish. Overview of tumor cell-based vaccines. Int. Rev. Immunol. 25:297-319 (2006).
54. S. Goto, A. Noguchi, H. Jinguji, and M. Takahara. The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates. Anticancer Res. 26:3989-3995 (2006).
55. K. M. Jacobsohn and C. G. Wood. Adjuvant therapy for renal cell carcinoma. Semin. Oncol. 33:576-582 (2006).
56. G. C-cile, S. Arnulf, S. Stefan, and R. Hans-Georg. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 56:117-128(2007).
57. D. Cross, and J. K. Burmester. Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4:218-227 (2006).
58. S. Shu, J.C. Alistair, R.R. Huang, L.M. Donald, and T.M. Holden, Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy. Cancer Metastasis Rev. 25:233-242 (2006).
59. J. A. Berzofsky, M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113:1515-1525 (2004).
60. M. Harris. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5:292-302 (2004).
61. L. Muller and G. Pawelec. Cytokines and antitumor immunity. Technol. Cancer Res. Treat. 2:183-194 (2003).
62. J. Atzpodien, R. Hoffmann, M. Franzke, C. Stief, T. Wandert, and M. Reitz. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95:1045-1050 (2002).
63. A. H. Baselmans, J. W. Koten, J. J. Battermann, J. E. Van Dijk, and O. W. Den. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol. Immunother. 51:492-498 (2002).
64. R. M. Steinman and M. Pope. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109:1519-1526 (2002).
65. S. Nawrocki, P.J. Wysocki, A. Mackiewicz. Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin. Biol. Ther. 1:193-204 (2001).
66. T. Kikuchi. Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. 208:1-8 (2006).
67. J. W. Hodge, J. W. Greiner, K. Y. Tsang, H. Sabzevari, C. Kudo-Saito, D. W. Grosenbach, J. L. Gulley, P. M. Arlen, J. L. Marshall, D. Panicali, J. Schlom. Costimulatory molecules as adjuvants for immunotherapy. Front. Biosci. 11:788-803 (2006).
68. G.G. Leichman, D. Woytowitz, D. Mezger, J. Albert, G. Schmalbach, T. Al-Adhami, and M. Manegold. CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. ASCO Annual Meeting. Abstract 7039 (2005).
69. H. Richard, J. Justin, and W.C. Miles. Recombinant viral vectors: Cancer vaccines. Adv. Drug Deliv. Rev. 58:931-947 (2006).
70. J. Nemunaitis. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J. Control. Release 91:225-231 (2003).
71. J. Nemunaitis, J. Schiller, H. Ross, D. Jablons, H. Harper, D. Sterman, K. Kelly, D. Carbone, A. Lin, D. Maslyar, and K. Hege. A phase 2 randomized study of GM-CSF gene-modified autologous tumor cell immunotherapy (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC). Mol. Ther. 13:S243 (2006).
72. R. A. Figlin, W. C. Pierce, R. Kaboo, C. L. Tso, N. Moldawer, B. Gitlitz, J. deKernion, and A. Belldegrun. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor inWltrating lymphocytes from primary tumor. J. Urol. 158:740-745 (1997).
73. N. F. Gordon, and B. L. Clark. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 32:63-69 (2004).
74. J. Nemunaitis, T. Jahan, H. Ross, D. Sterman, D. Richards, B. Fox, D. Jablons, J. Aimi, A. Lin, and K. Hege. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 13:555-562 (2006).
75. R. T. Costello, F. Mallet, B. Barbarat, J. M. Schiano De Colella, D. Sainty, R. W. Sweet, A. Truneh, and D. Olive. Stimulation of non-Hodgkin s lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 17:2500-2507 (2003).
76. B. Homey, A. Muller, and A. Zlotnik. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2:175-184 (2002).
77. L. Zhang, J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, S. C. Rubin, and G. Coukos. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213 (2003).
78. M. Baggiolini. Chemokines in pathology and medicine. J. Intern. Med. 250:91-104 (2001).
79. A. Zlotnik, O. Yoshie, and H. Nomiyama. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7:243 (2006).
80. R. Benelli, G. Lorusso, A. Albini, and D. M. Noonan. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr. Pharm. Des. 12:3101-3115 (2006).
81. N. M. Rebenko-Moll, L. Liu, A. Cardona, and R. M. Ransohoff. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details. Curr. Opin. Immunol. 18:683-689 (2006).
82. M. Baggiolini. Chemokines in pathology and medicine. J. Intern. Med. 250:91-104 (2001).
83. M. Maurer and S. E. von. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 36:1882-1886 (2004).
84. M. J. Robertson. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 71:173-183 (2002).
85. M. Ogris and E. Wagner. Targeting tumors with non-viral gene delivery systems. Drug Discov. Today 7:479-485 (2002).
86. W. C. Russell. Update on adenovirus and its vectors. J. Gen. Virol. 81:2573-2604 (2000).
87. J. G. Altin and C. R. Parish. Liposomal vaccines-targeting the delivery of antigen. Methods 40:39-52 (2006).
88. J. A. St George. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 10:1135-1141 (2003).
89. J. M. Lee, R. E. Merritt, A. Mahtabifard, R. Yamada, T. Kikuchi, R. G. Crystal, and R. J. Korst. Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J. Immunother. 26:117-129 (2003).
90. T. Tsuchiyama, S. Kaneko, Y. Nakamoto, Y. Sakai, M. Honda, N. Mukaida, and K. Kobayashi. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther. 10:260-269 (2003).
91. I. Narvaiza, G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, and J. Prieto. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164:3112-3122 (2000).
92. H. Mizuguchi and M. A. Kay. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9:2577-2583 (1998).
93. H. Mizuguchi, M. A. Kay, and T. Hayakawa. In vitro ligation-based cloning of foreign DNAs into the E3 and E1 deletion regions for generation of recombinant adenovirus vectors. Biotechniques 30:1112-1114 (2001).
94. N. Okada, Y. Tsukada, S. Nakagawa, H. Mizuguchi, K. Mori, T. Saito, T. Fujita, A. Yamamoto, T. Hayakawa, and T. Mayumi. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun. 282:173-179 (2001).
95. Y. Okada, N. Okada, S. Nakagawa, H. Mizuguchi, K. Takahashi, N. Mizuno, T. Fujita, A. Yamamoto, T. Hayakawa, and T. Mayumi. Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn. J. Cancer Res. 93:436-444 (2002).
96. Y. Okada, N. Okada, S. Nakagawa, H. Mizuguchi, M. Kanehira, N. Nishino, K. Takahashi, N. Mizuno, T. Hayakawa, and T. Mayumi. Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett. 177:57-63 (2002).
97. H. Xin, T. Kikuchi, S. Andarini, S. Ohkouchi, T. Suzuki, T. Nukiwa, Huqun, K. Hagiwara, T. Honjo, and Y. Saijo. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur. J. Immunol. 35:1371-1380 (2005).
98. T. Fushimi, T. P. O Connor, and R. G. Crystal. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res. 66:3513-3522 (2006).
99. Y. Sun, C. Finger, L. varez-Vallina, K. Cichutek, and C. J. Buchholz. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther. 12:900-912 (2005).
100. M. Shi, S. Hao, L. Su, X. Zhang, J. Yuan, X. Guo, C. Zheng, and J. Xiang. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses. Cancer Biother. Radiopharm. 20:401-409 (2005).
101. A. Muhs, M. C. Lenter, R. W. Seidler, R. Zweigerdt, M. Kirchengast, R. Weser, M. Ruediger, and B. Guth. Nonviral monocyte chemoattractant protein-1 gene transfer improves arteriogenesis after femoral artery occlusion. Gene Ther. 11:1685-1693 (2004).
102. M. Maric and Y. Liu. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res. 59:5549-5553 (1999).
103. E. Nakashima, A. Oya, Y. Kubota, N. Kanada, R. Matsushita, K. Takeda, F. Ichimura, K. Kuno, N. Mukaida, K. Hirose, I. Nakanishi, T. Ujiie, and K. Matsushima. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13:1896-1901 (1996).
104. R. Liu, C. Zhou, D. Wang, W. Ma, C. Lin, Y. Wang, X. Liang, J. Li, S. Guo, Y. Wang, Y. Zhang, and S. Zhang. Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes. Cancer Biol. Ther. 5:427-434 (2006).
105. S. Ozawa, Y. Kato, R. Komori, Y. Maehata, E. Kubota, and R. Hata. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem. Biophys. Res. Commun. 348:406-412 (2006).
106. J. Guo, B. Wang, M. Zhang, T. Chen, Y. Yu, E. Regulier, H. E. Homann, Z. Qin, D. W. Ju, and X. Cao. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 9:793-803 (2002).
107. T. Ishida and R. Ueda. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 97:1139-1146 (2006).
108. T. Nomura, H. Hasegawa, M. Kohno, M. Sasaki, and S. Fujita. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int. J. Cancer. 91:597-606 (2001).
109. D. Dilloo, K. Bacon, W. Holden, W. Zhong, S. Burdach, A. Zlotnik, and M. Brenner. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 2:1090-1095 (1996).
110. M. Maric, L. Chen, B. Sherry, and Y. Liu. A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha. J. Immunol. 159:360-368 (1997).
111. P. C. Emtage, Y. Wan, M. Hitt, F. L. Graham, W. J. Muller, A. Zlotnik, and J. Gauldie. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10:697-709 (1999).
112. J. Q. Gao, N. Kanagawa, Y. Motomura, T. Yanagawa, T. Sugita, Y. Hatanaka, Y. Tani, H. Mizuguchi, Y. Tsutsumi, T. Mayumi, N. Okada, and S. Nakagawa. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther. 14:491-502 (2007).
113. N. Okada, A. Sasaki, M. Niwa, Y. Okada, Y. Hatanaka, Y. Tani, H. Mizuguchi, S. Nakagawa, T. Fujita, and A. Yamamoto. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther. 13:393-405 (2006).
114. E. J. Weinstein, R. Head, D. W. Griggs, D. Sun, R. J. Evans, M. L. Swearingen, M. M. Westlin, and R. Mazzarella. VCC-1, a novel chemokine, promotes tumor growth. Biochem. Biophys. Res. Commun. 350:74-81 (2006).
115. T. Kuroda, Y. Kitadai, S. Tanaka, X. Yang, N. Mukaida, M. Yoshihara, and K. Chayama. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res. 11:7629-7636 (2005).
116. H. Kang, R. E. Mansel, and W. G. Jiang. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int. J. Oncol. 26:1429-1434 (2005).
117. H. Kang, G. Watkins, C. Parr, A. Douglas-Jones, R. E. Mansel, and W. G. Jiang. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 7:R402-R410 (2005).
118. Y. Zhou, J. Zhang, Q. Liu, R. Bell, D. A. Muruve, P. Forsyth, M. rcellana-Panlilio, S. Robbins, and V. W. Yong. The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis 26:2058-2068 (2005).
119. R. M. Steinman, M. Witmer-Pack, and K. Inaba. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 329:1-9 (1993).
120. M. E. Dudley, J. R. Wunderlich, P. F. Robbins, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854 (2002).
121. M. E. Dudley, J. R. Wunderlich, J. C., Yang, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357 (2005).
122. M. S. Mitchell, J. Kan-Mitchell, R. A. Kempf, et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48:5883-5893 (1988).
123. D. L. Morton, E. C. Hsueh, R. Essner, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 236:438-448 (2002).
124. G. Dranoff. GM-CSF-secreting melanoma vaccines. Oncogene 22:3188-3192 (2003).
125. S. Ward, D. Casey, M. C. Labarthe, et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51:351-357 (2002).
126. J. Banchereau, and A. K. Palucka, Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306 (2005).
127. C. G. Figdor, I. J. de Vries, W. J. Lesterhuis, et al. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480 (2004).
128. P. Moingeon. Cancer vaccines. Vaccine 19:1305-1326 (2001).
129. N. Renkvist, C. Castelli, P. F. Robbins, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3-15 (2001).
130. J. M. Austyn. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183:1287-1292 (1996).
131. R. N. Germain and D. H. Margulies. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403-450 (1993).
132. F. O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, D. Schadendorf. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat. Med. 4:328-332 (1998).
133. B. Schuler-Thurner, E.S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte derived dendritic cells. J. Exp. Med. 195:1279-1288 (2002).
134. Z. Su, J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J.Vieweg. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2127-2133 (2003).
135. P. A. Lodge, L. A. Jones, R. A. Bader, G. P. Murphy, and M. L. Salgaller. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res. 60:829-833 (2000).
136. P. Brossart, S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108 (2000).
137. J. S. Yu, C. J. Wheeler, P. M. Zeltzer, H. Ying, D. N. Finger, P. K. Lee, W. H. Yong, F. Incardona, R. C. Thompson, M. S. Riedinger, W. Zhang, R. M. Prins, and K. L. Black. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61:842-847 (2001).
138. B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, E. B. Brocker, R.M. Steinman, A. Enk, E., and G. Kampgen. Vaccination with mage-3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678 (1999).
139. A. Tuettenberg, E. Schmitt, J. Knop, and H. Jonuleit. Dendritic Cell-Based Immunotherapy of Malignant Melanoma: Success and Limitations. J. Dtsch. Dermatol. Ges. 5:190-196 (2007).
140. A. Mackensen, B. Herbst, J. L. Chen, G. Kohler, C. Noppen, W. Herr, G. C. Spagnoli, V. Cerundolo, and A. Lindemann. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34 hematopoietic progenitor cells. Int. J. Cancer. 86:385-392 (2000).
141. J. Banchereau, A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K. M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman, and J. Fay. Immune and clinical responses in patients with metastatic melanoma to CD34 progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-6458 (2001).
142. H. Jonuleit, A. Giesecke-Tuettenberg, T. Tuting, B. Thurner-Schuler, T.B. Stuge, L. Paragnik, A. Kandemir, P.P. Lee, G. Schuler, J. Knop, and A.H. Enk. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer. 93:243-251 (2001).
143. N. Okada, T. Saito, Y. Masunaga, Y. Tsukada, S. Nakagawa, H. Mizuguchi, K. Mori, Y. Okada, T. Fujita, T. Hayakawa, T. Mayumi, and A. Yamamoto. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 61:7913-7919 (2001).
144. N. Okada, Y. Masunaga, Y. Okada, H. Mizuguchi, S. Iiyama, N. Mori, A. Sasaki, S. Nakagawa, T. Mayumi, T. Hayakawa, T. Fujita, and A. Yamamoto. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 10:1891-1902 (2003).
145. M. D. Gunn, S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, and H. Nakano. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451-460 (1999).
146. R. Forster, A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33 (1999).
147. N. Okada, N. Mori, R. Koretomo, Y. Okada, T. Nakayama, O. Yoshie, H. Mizuguchi, T. Hayakawa, S. Nakagawa, T. Mayumi, T. Fujita, and A. Yamamoto. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 12:129-139 (2005).
148. S. C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 66:3205-3213 (2006).
149. M. Nukiwa, S. Andarini, J. Zaini, H. Xin, M. Kanehira, T. Suzuki, T. Fukuhara, H. Mizuguchi, T. Hayakawa, Y. Saijo, T. Nukiwa, and T. Kikuchi. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur. J. Immunol. 36:1019-1027 (2006).
150. S. Matthias. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer 13:779-795 (2006).
151. P. Klenerman, V. Cerundolo, and P. R. Dunbar. Tracking T cells with tetramers: new tales from new tools. Nat. Rev. Immunol. 2:263-272 (2002).
152. N. Verra, D. de Jong, A. Bex, et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur. Urol. 48:527-33 (2005).
153. S. Dessureault, D. Noyes, D. Lee, et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol. 14:869-84 (2007).
154. R. J. Vuylsteke, B. G. Molenkamp, H. A. Gietema, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 64:8456-60 (2004).
155. C. M. van Herpen, J. A. van der Laak, I. J. de Vries, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin. Cancer Res. 11:1899-1909 (2005).
156. A. Giannopoulos, C. Constantinides, E. Fokaeas, et al. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res. 9:5550-5558 (2003).
157. F. Romano, G. Cesana, R. Caprotti, et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology 53:634-638 (2006).
158. R. F. Rousseau, A. E. Haight, C. Hirschmann-Jax, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718-26 (2003).
159. A. S. Jorkov, F. Donskov, T. Steiniche, et al. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. Anticancer Res. 23:537-542 (2003).
160. K. Tani, M. Azuma, Y. Nakazaki, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. 10:799-816 (2004).
161. E. Galanis, P. A. Burch, R. L. Richardson, et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 101:2557-2566 (2004).
162. R. S. Barnetson, A. Satchell, L. Zhuang, H. B. Slade, G. M. Halliday. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin. Exp. Dermatol. 29:639-43 (2004).
163. B. Thurner, I. Haendle, C. Roder, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-78 (1999).
164. D. H. Chang, K. Osman, J. Connolly, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201:1503-17 (2005).
165. J. A. Kyte, L. Mu, S. Aamdal, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13:905-918 (2006).
166. J. Guo, J. Zhu, X. Sheng, et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int. J. Cancer 120:2418-25 (2007).
167. N. Nakai, J. Asai, E. Ueda, et al. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J. Dermatol. 33:462-72 (2006).
168. L. H. Butterfield, A. Ribas, V. B. Dissette, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 12:2817-25 (2006).
169. A. K. Thomas-Kaskel, R. Zeiser, R. Jochim, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119:2428-2434 (2006).
170. B. Hildenbrand, B. Sauer, O. Kalis, et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate 67:500-508 (2007).
171. J. Westermann, J. Kopp, A. Van Lessen, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 137:297-306 (2007).
172. T. Maier, A. Tun-Kyi, A. Tassis, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102:2338-2344 (2003).
173. F. O. Nestle, S. Alijagic, M. Gilliet, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-32 (1998).
174. J. Banchereau, A. K. Palucka, M. Dhodapkar, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-8 (2001).